STAT Plus: Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it

Q32 Bio has two targets in its sights: the two arms of the immune system.

The Cambridge, Mass., startup on Wednesday announced $46 million in Series A financing led by Atlas Venture, and disclosed it aims to address problems with both innate immunity, the body’s initial response to an invader, and adaptive immunity, which develops antibodies to the foreign interloper. 

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it »